Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected at $2.91 after the company reported Q1 results.
Earnings per share rose 65.00% year over year to ($0.07), which beat the estimate of ($0.17).
Revenue of $13,261,000 up by 55.19% year over year, which beat the estimate of $8,840,000.
Earnings guidance hasn't been issued by the company for now.
Pieris Pharmaceuticals hasn't issued any revenue guidance for the time being.
Recent Stock Performance
Company's 52-week high was at $6.04
Company's 52-week low was at $1.60
Price action over last quarter: Up 34.72%
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.